Chronic spontaneous urticaria (CSU) is a distressing and unpredictable disease characterized by the spontaneous appearance of wheals (hives) and/or angioedema for >6 weeks due to unknown or unknown causes in the absence of specific and definite stimuli. CSU can have a substantial negative impact on patients’ quality of life (QoL), and it often does so with a significant burden of disease and healthcare costs.

Randomized patients (N=311) were aged 45.0±14.9 (SD) years, 71.4% female, and had lived with CSU for ≥6 months which was inadequately controlled by second-generation H1-antihistamines and were on background H1-antihistamines and rescue therapy when needed.

Data reported in the current study were collected during a 12-week treatment period (Figure 1).

Patients were randomized 1:1:1:1:1 to receive remibrutinib 10 mg qd (once daily), 10 mg bid (twice daily), 25 mg bid, 50 mg bid, or placebo.

The outcome reported here is DLQI (range 0-30) in which a decreased score indicates improved QoL, and a score of 0-1 indicates no disease effect on QoL.

Changes in DLQI score from baseline to Week 4 and 12 and proportions of patients achieving DLQI=0-1 at Week 4 and 12 were numerically greater in all remibrutinib groups compared to placebo (Figures 3 & 4).

**CONCLUSION**

Compared to placebo, all remibrutinib doses provided marked improvements in DLQI as early as Week 4, which were maintained at Week 12.

These findings are consistent with the previously reported results of remibrutinib treatment on weekly Urticaria Activity Score (UAS).

**References**

6. Maurer M et al. EADV 29th September-2nd October, 2021. Virtual World Congress of AAD. Published online: no. 27RAD

**Conflict of interest**

Maurer M is a receipient of advisory board payments from Genentech, GSK, Abbvie, and Bausch. He is a consultant for Novartis Pharma AG, Basel, Switzerland. Jain V is an employee of Novartis Pharma AG, Basel, Switzerland. Walsh P is an employee of Novartis AG. Hayama K is an employee of Novartis Pharma AG, Basel, Switzerland.

Maurer M has served as a member of advisory boards for Genentech, Novartis, Genzyme, and SanoPharma. Jain V has served as a consultant for Genentech, Novartis, Genzyme, and SanoPharma. Walsh P has served as a consultant for Genentech, Novartis, Genzyme, and SanoPharma. Hayama K has served as a consultant for Novartis, Sun Pharma, and Taiho.

Hayama K, Jain V, and Walsh P are employees of Novartis Pharma AG, Basel, Switzerland. Maurer M is an employee of Novartis Pharma AG, Basel, Switzerland. Gaetano L is an employee of Novartis.

**Acknowledgements**

Medical writing support was provided by Linda Nassar, PhD and Carol H Diaz, PhD of Novartis Healthcare, in accordance with Good Publication Practice (GPP3) guidelines. Medical writing support was provided by Novartis.

**Funding**

This study was supported by a grant from Novartis to the German Society for Allergy and Immunology (DAAI) 2022 Annual Meeting, 28-31 January 2022, Prague, Czech Republic.